DKTK-Studienregister

DetailsucheDetailsuche
Klicken Sie auf Detailsuche, um z.B. nach Therapielinie, molekularem Marker oder Rekrutierungsstatus zu suchen.
FreitextsucheFreitextsuche
Sie können hier nach dem Studienkurzcode oder einem Teil des Studientitels suchen.
Studienauswahl
Zentren
Status der Studie

» Gynäkologische Onkologie » Mamma-Ca

Alle Linien

CAPITELLO-291 (D3615C00001)
Eine doppelblinde, randomisierte Phase-III-Studie zur Bewertung der Wirksamkeit und Sicherheit von Capivasertib + Fulvestrant im Vergleich zu Placebo + Fulvestrant zur Behandlung von lokal fortgeschrittenem (inoperablem) oder metastasiertem Hormonrezeptor-positivem, humanem epidermalem Wachstumsfaktor-Rezeptor 2 negativem (HR+/HER2-) Brustkrebs nach Rezidiv oder Progression während oder nach der Behandlung mit einem Aromatasehemmer (Aktiv)

DETECT V
Detect V / CHEVENDO (Chemo vs. Endo) (Aktiv)

LIBRE
Prospektive randomisierte multizentrische Studie zur Untersuchung der Machbarkeit eines strukturierten körperlichen Bewegungsprogramms und einer mediterranen Ernährung bei Frauen mit BRCA1/2-Mutationen (Aktiv)

LIBRE-2
Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers (Aktiv)

OnkoFit I
Trial Evaluating the Benefit of a Fitness Tracker Based Workout During Adjuvant Radiotherapy of Breast Cancer (Aktiv)

RIBBIT
Klinische Studie zur Untersuchung der Wirksamkeit und der Lebensqualität von postmenopausalen Patientinnen mit metastasiertem HER2-negativem, Hormonrezeptor-positivem Brustkrebs unter Erstlinienbehandlung mit einer Kombinationstherapie aus Ribociclib und einem Aromataseinhibitor oder einer Therapie mit Paclitaxel mit / ohne Bevacizumab (Aktiv)

SAVE-HEART
Cardiac Safety Study in Patients With HER2 + Breast Cancer (SAFE-HEaRt) (Aktiv)

STARTRK-2
Studie der Phase II zu Entrectinib bei Patienten soliden Tumoren, die ein NTRK1/2/3-, ROS1- oder ALK-Gen-Rearrangement aufweisen (Aktiv)

Seno_Ex_MAC 003
Comparison of Conventional With Sonography Assisted Breast Surgery (Aktiv)

Seno_Ex_MARGIN-II
MOLEKULARE FLUORESZENZ-GESTEUERTE OPERATION UNTER ANWENDUNG VON BEVA800 ZUR BEWERTUNG VON TUMORRÜCKSTÄNDEN (Aktiv)

TNBC-MORPHEUS
A Study to Evaluate Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic Triple-Negative Breast Cancer (MORPHEUS-TNBC) (Aktiv)

UC02-PSMA-01
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker (Aktiv)

VIOLETTE
A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair (Aktiv)

Erstlinie

ADAPT
Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer (Aktiv)

ADAPT Elderly
A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response (Aktiv)

ATZ-1068-KRA-20I
HER2-Peptide Vaccination of Patients With Solid Tumors (Aktiv)

BENEFIT
Exercise Interventions for Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (Aktiv)

BZ_neoMono (neoMono)
Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (Aktiv)

CARL
Feasibility of extracorporeal elimination by double membrane plasmapheresis (Aktiv)

COSMOPOLITAN
Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer (Aktiv)

ECLIPSE
A phase II study investigating preoperative combination strategies for immunotherapy in patients with untreated, operable oestrogen receptor positive primary breast cancer (Aktiv)

Ember 2
A Phase 1, Open-Label, Preoperative Window Study evaluating the Biological Effects of LY3484356 in Post-menopausal Women with Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer (Aktiv)

Expression
Neoadjuvant, sequential chemotherapy with docetaxel followed by Fluorouracil, Epirubicin, and Cyclophosphamid every 3 weeks - genome wide expression analysis for identification of a predictive gene signature in patients with primary breast cancer (Aktiv)

GALADON
Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON) (Aktiv)

HYPOSIB
Hypofractionation with simultaneous integrated boost has been investigated in a few trials and appears to be safe and feasible. Investigators initiated this multicenter two-armed phase III prospective trial to analyse the non-inferiority of hypofractionation with simultaneous integrated boost in patients with early breast cancer in comparison to standard fractionation. (Aktiv)

INSEMA (GBG 75)
The objective of INSEMA is to show that less axillary surgery is better, in that oncological outcomes are the same and less surgical intervention will result in fewer surgical complications. (Aktiv)

IPATunity 130
This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2−) breast adenocarcinoma who are not suitable for endocrine therapy. (Aktiv)

Impassion 131
A PHASE III, MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER (Aktiv)

PALLAS
A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive/HER2-negative early breast cancer (Aktiv)

PIKTAM
Clinical trial of BKM120 in combination with tamoxifen in patients with breast cancer (hormone receptor-positive, HER2-negative, inoperable, locally advanced or metastatic) (Aktiv)

SGNLVA-002
Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer (Aktiv)

Zweitlinie oder später

ADAPTlate
Adjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy in (Clinical or Genomic) High Risk, HR+/HER2- Early Breast Cancer (ADAPTlate) (Aktiv)

AMICA
Anti-hormonal Therapie With or Without Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (AMICA) (Aktiv)

BO41483
A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (Aktiv)

CNIR178X2201
Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)

DESTINY-Breast06 (D9670C00001)
Eine randomisierte, multizentrische, offene Phase-III-Studie mit Trastuzumab Deruxtecan (T-DXd) im Vergleich zur Chemotherapie nach Wahl des Prüfarztes bei HER2-niedrigen, hormonrezeptorpositiven Brustkrebspatientinnen, deren Erkrankung während einer endokrinen Therapie im metastasierten Setting fortgeschritten ist (Aktiv)

DESTINY-Breast12 (D9673C00007)
Eine offene, multinationale, multizentrische Phase-IIIb/IV-Studie mit Trastuzumab Deruxtecan bei Patienten mit oder ohne zu Studienbeginn vorliegender Hirnmetastasierung mit vorbehandeltem fortgeschrittenem/metastasiertem HER2-positivem Brustkrebs (Aktiv)

DS8201-A-U105 - Daiichi Sankyo
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer (Aktiv)

Detect IV
An open label, non-randomized phase II trial of Everolimus (Aktiv)

GEM3PSCA-01
Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker (Aktiv)

IMpassion030
A Study to Compare Atezolizumab (Anti-PD-L1 Antibody) in Combination with Adjuvant Anthracycline/Taxane based Chemotherapy Versus Chemotherapy Alone in Patients with Operable Triple-Negative Breast Cancer (Aktiv)

Imcheck ICT01-101 (EVICTION)
First-in-Human Study of ICT01 in Patients With Advanced Cancer (Aktiv)

MK-7684A-005
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (Aktiv)

MedOPP068
PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (Aktiv)

PADMA
The study aims to compare the time-to-treatment failure of a palbociclib + endocrine therapy against a pre-chosen mono-chemotherapy in a real world setting. Time-to-treatment failure (TTF) is defined as time from randomization to discontinuation of treatment due to disease progression, treatment toxicity, patient’s preference, or death. (Aktiv)

PRECYCLE
Impact of eHealth-support on Quality of Life in metastatic breast cancer patients treated with Palbociclib and endocrine therapy (Aktiv)

SORATRAM
Multizentrische Basket-Studie zur kombinierten CRAF- und MEK-Inhibition bei fortgeschrittenen Tumorerkrankungen mit BRAF-Mutationen und eingeschränkter Kinase-Aktivität (Aktiv)

DKTK-Studienregister
Dr. N. Gökbuget, Dipl.-Biol. K. Ihrig | Ohne Gewähr für Richtigkeit oder Vollständigkeit | ccp@dkfz.de